Brief: Cocrystal Pharma Engages Cro To Conduct Phase 2A Human Challenge Influenza A Clinical Trial With Candidate CC-42344
08/08/2022 13:10
Aug 8 (Reuters) -
* COCRYSTAL PHARMA ENGAGES CRO TO CONDUCT PHASE 2A HUMAN CHALLENGE INFLUENZA
A
CLINICAL TRIAL WITH NOVEL, BROAD-SPECTRUM ANTIVIRAL CANDIDATE CC-42344
* COCRYSTAL PHARMA INC - CONDUCTING A PHASE 1 STUDY WITH CC-42344 IN HEALTHY
SUBJECTS IN AUSTRALIA
Source text for Eikon: ID:nGNX94VBMD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway